2016 American Transplant Congress
Black Ethnicity as a Risk Factor for Poor Kidney Allograft Outcomes Post-Transplantation.
Introduction: Registry studies, largely from the United States, have consistently demonstrated inferior outcomes for black patients undergoing renal transplant. A recent Canadian publication has challenged…2016 American Transplant Congress
Induction Therapy in Low Risk African American Kidney Transplant Recipients: Donor Factors.
African Americans (AA) are at a higher risk of acute rejection and graft loss compared to non-AA kidney transplant (KT) recipients. Guidelines specify induction choices…2016 American Transplant Congress
Early Steroid Withdrawal in African American Kidney Transplant Recipients: A Propensity Score Matching Analysis.
Objective: The aim of this study was to assess the safety of steroid withdrawal in African American (AA) kidney transplant (KTX) recipients.Methods: Longitudinal cohort study…2016 American Transplant Congress
Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.
Studies consistently show worse outcomes for black vs non-black kidney transplant recipients. At 7 yrs post-transplant in BENEFIT-EXT (NCT00114777), bela was associated with similar graft…2016 American Transplant Congress
Lower Rates of Living Donor Kidney Transplantation(LD) Among African Americans: What Prevents Higher Rates of Donation?
MedStar Georgetown Transplant Institute, Washington, DC.
Purpose: African Americans (AA) are less likely to undergo LD kidney transplantation. Reasons may include decreased health literacy, increased obesity, or hypertension. We sought to…2016 American Transplant Congress
Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT.
Studies consistently show worse outcomes for black vs non-black kidney transplant recipients. At 7 yrs post-transplant in BENEFIT, bela was associated with superior graft survival…2016 American Transplant Congress
Hospitalization and Living Donor Kidney Transplantation Among Waitlisted End Stage Renal Disease Patients in the US.
Background: For End Stage Renal Disease Patients (ESRD) waitlisted for a deceased donor kidney, living donor kidney transplantation (LDKT) could allow for earlier transplantation and…2016 American Transplant Congress
Evaluating the Influence of Liver Donor and Recipient Race on Tacrolimus Dose Requirements.
Einstein Medical Center, Philadelphia, PA.
Background: The majority of liver transplant recipients (LTR) receive tacrolimus (TAC) to prevent allograft rejection. Early establishment of therapeutic levels is imperative to efficacy. Several…2016 American Transplant Congress
Why Do African American Patients Display Disparities in Renal Graft Function Following Renal Transplantation?
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
Objective: The aim of this study was to assess disparities in post-operative mortality and graft failure among patients of African and European ancestry undergoing kidney…2016 American Transplant Congress
Therapeutically Equivalent Results to Caucasians in Black Kidney Transplant Recipients Using ASTAGRAF XL® Despite a Higher Degree of HLA Mismatch : A Post-Hoc Analysis of Phase III Data from Over 2000 Patients.
Astelleas Pharma Global Develepment, Northbrook, IL.
INTRO: When contemplating the use of a new immunosuppressant agent in kidney transplantation, measuring outcomes in potentially vulnerable populations is of paramount concern. As such,…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 23
- Next Page »